Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis
Sponsor: Incyte Corporation
This PHASE3 trial investigates Atopic Dermatitis (AD) and is currently completed. Incyte Corporation leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Completed PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 6 earlier versions
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — May 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Jun 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Incyte Corporation
For direct contact, visit the study record on ClinicalTrials.gov .